RSS   Newsletter   Contact   Advertise with us
Post Online Media

Novartis appoints leaders for two new business units

NovartisNovartis Pharmaceuticals and Novartis Oncology to form the Innovative Medicines Division at Novartis. The leader of each business will join the executive committee of Novartis, effective July 1, 2016.
Article continues below

READ MORE Qu Biologics appoints former Novartis president to the board

Paul Hudson will be appointed CEO, Novartis Pharmaceuticals.

Mr. Hudson, currently Executive Vice President, North America and member of the Executive Committee, AstraZeneca, will join Novartis and lead Novartis Pharmaceuticals.

Prior to his role in North America, Mr. Hudson served as the leader of AstraZeneca's Japanese business. Novartis Pharmaceuticals will include the franchises Neuroscience, Ophthalmology, Immunology and Dermatology, Respiratory, Cardio-Metabolic and Established Medicines.

Mr. Hudson has broad pharmaceutical industry experience and in particular in cardiovascular and immunology, which complement Novartis' major product launches.

Bruno Strigini will become CEO, Novartis Oncology.

Mr. Strigini, currently Head of Novartis Oncology, will lead the Novartis Oncology business unit, comprised of the franchises Oncology and Cell and Gene Therapies.

Mr. Strigini joined Novartis in 2014 from Merck & Co. to lead the oncology business and was instrumental in the successful integration of the oncology assets acquired from GSK.

David Epstein, currently Division Head and CEO of Novartis Pharmaceuticals, has decided to leave Novartis and explore new challenges from the US.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy